NASDAQ: INO
Inovio Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

Analyst price target for INO

Based on 1 analyst offering 12 month price targets for Inovio Pharmaceuticals Inc

Min Forecast
$2.50+125.23%
Avg Forecast
$2.50+125.23%
Max Forecast
$2.50+125.23%

Should I buy or sell INO stock?

Based on 1 analyst offering ratings for Inovio Pharmaceuticals Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although INO's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates INO as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their INO stock forecasts and price targets.

INO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-06-01

1 of 1

Forecast return on equity

Is INO forecast to generate an efficient return?

Company
643.64%
Industry
93.31%
Market
176.08%
INO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is INO forecast to generate an efficient return on assets?

Company
78.46%
Industry
27.35%
INO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

INO earnings per share forecast

What is INO's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
-$0.89
Avg 2 year Forecast
-$0.44
Avg 3 year Forecast
$0.58

INO revenue forecast

What is INO's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$14.0M
Avg 2 year Forecast
$62.5M
Avg 3 year Forecast
$132.9M

INO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
INO$1.11$2.50+125.23%Hold
BDTX$1.61$11.00+583.23%Strong Buy
LIXT$7.48N/AN/A
PYPD$5.13$13.00+153.41%Buy
AARD$4.08$13.14+222.13%Buy

Inovio Pharmaceuticals Stock Forecast FAQ

Is Inovio Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: INO) stock is to Hold INO stock.

Out of 1 analyst, 0 (0%) are recommending INO as a Strong Buy, 0 (0%) are recommending INO as a Buy, 1 (100%) are recommending INO as a Hold, 0 (0%) are recommending INO as a Sell, and 0 (0%) are recommending INO as a Strong Sell.

If you're new to stock investing, here's how to buy Inovio Pharmaceuticals stock.

What is INO's earnings growth forecast for 2026-2028?

(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.51%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Inovio Pharmaceuticals's earnings in 2026 is -$84,934,002.On average, 7 Wall Street analysts forecast INO's earnings for 2026 to be -$73,321,909, with the lowest INO earnings forecast at -$84,659,161, and the highest INO earnings forecast at -$57,879,222. On average, 6 Wall Street analysts forecast INO's earnings for 2027 to be -$35,879,359, with the lowest INO earnings forecast at -$77,402,661, and the highest INO earnings forecast at -$2,509,334.

In 2028, INO is forecast to generate $48,031,116 in earnings, with the lowest earnings forecast at -$9,675,333 and the highest earnings forecast at $95,889,458.

What is INO's revenue growth forecast for 2026-2028?

(NASDAQ: INO) Inovio Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.99%.

Inovio Pharmaceuticals's revenue in 2026 is $0.On average, 7 Wall Street analysts forecast INO's revenue for 2026 to be $1,150,015,307, with the lowest INO revenue forecast at $0, and the highest INO revenue forecast at $3,586,784,040. On average, 6 Wall Street analysts forecast INO's revenue for 2027 to be $5,145,285,969, with the lowest INO revenue forecast at $838,528,832, and the highest INO revenue forecast at $10,572,110,955.

In 2028, INO is forecast to generate $10,934,113,197 in revenue, with the lowest revenue forecast at $5,135,989,093 and the highest revenue forecast at $17,561,222,438.

What is INO's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: INO) forecast ROA is 78.46%, which is higher than the forecast US Biotechnology industry average of 27.35%.

What is INO's Price Target?

According to 1 Wall Street analyst that have issued a 1 year INO price target, the average INO price target is $2.50, with the highest INO stock price forecast at $2.50 and the lowest INO stock price forecast at $2.50.

The Wall Street analyst predicted that Inovio Pharmaceuticals's share price could reach $2.50 by Jun 1, 2027. The average Inovio Pharmaceuticals stock price prediction forecasts a potential upside of 125.23% from the current INO share price of $1.11.

What is INO's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: INO) Inovio Pharmaceuticals's current Earnings Per Share (EPS) is -$1.45. On average, analysts forecast that INO's EPS will be -$0.89 for 2026, with the lowest EPS forecast at -$1.03, and the highest EPS forecast at -$0.70. On average, analysts forecast that INO's EPS will be -$0.44 for 2027, with the lowest EPS forecast at -$0.94, and the highest EPS forecast at -$0.03. In 2028, INO's EPS is forecast to hit $0.58 (min: -$0.12, max: $1.17).

What is INO's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: INO) forecast ROE is 643.64%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.